Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Same Mission, New Role for Genzyme Executive: Head of Rare Diseases Committed to Patients
January 21st 2012, 3:45pm
Updates From the ICHG/ASHG 61st Annual Meeting
Rogerio Vivaldi, MD, has vivid memories of the first patient with Gaucher disease ever treated in Brazil with enzyme replacement therapy.
Lysosomal Storage Disorders: Marking Milestones and Moving Forward
January 18th 2012, 3:03pm
Updates From the ICHG/ASHG 61st Annual Meeting
The mood of the ICHG/ASHG 2011 congress often seemed buoyant as researchers discussed the doors that technology is helping to open.
Dr. Grabowski Explains the Effects of Enzyme Therapy
January 14th 2012, 4:09pm
Updates From the ICHG/ASHG 61st Annual Meeting
Dr. Gregory Grabowski, from the University Cincinnati, Explains the Effects of Enzyme Therapy
Dr. Mistry Discusses His Experience With Gaucher Disease
January 11th 2012, 3:10pm
Updates From the ICHG/ASHG 61st Annual Meeting
Pramod K. Mistry, MD, PhD, from Yale University, discusses Gaucher disease
Dr. Mato on the Benefits of the JTCC Retrospective Trial
December 13th 2011, 4:27pm
ASH Annual Meeting and Exposition
Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial
Photos From the 2011 ASH Annual Meeting and Exposition
December 13th 2011, 4:06pm
ASH Annual Meeting and Exposition
A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.
Ponatinib Continues March to Potential Front-line Use in CML
December 13th 2011, 3:12pm
ASH Annual Meeting and Exposition
PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.
Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found
December 13th 2011, 10:07am
ASH Annual Meeting and Exposition
The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.
Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma
December 12th 2011, 2:19pm
ASH Annual Meeting and Exposition
Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.
Dr. Anasetti Discusses the Trade-offs of BMT and PBSC
December 12th 2011, 2:15pm
ASH Annual Meeting and Exposition
Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC
Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia
December 12th 2011, 11:19am
ASH Annual Meeting and Exposition
First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.
Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma
December 12th 2011, 10:22am
ASH Annual Meeting and Exposition
Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.
Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation
December 12th 2011, 9:36am
ASH Annual Meeting and Exposition
Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions
Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101
December 11th 2011, 1:37pm
ASH Annual Meeting and Exposition
Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101
Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia
December 11th 2011, 10:10am
ASH Annual Meeting and Exposition
Adding gemtuzumab to chemotherapy improved event-free and OS of newly diagnosed patients with acute myeloid leukemia.
Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)
December 11th 2011, 9:39am
ASH Annual Meeting and Exposition
Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).
Dr. Kochenderfer Discusses the B-cell Antigen CD19
December 10th 2011, 2:08pm
ASH Annual Meeting and Exposition
Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19
Dr. Feldman Discusses the Difficulties of Rare Lymphomas
December 10th 2011, 12:17pm
ASH Annual Meeting and Exposition
Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas
Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival
December 9th 2011, 4:16pm
San Antonio Breast Cancer Symposium
A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.
Photos From the 2011 San Antonio Breast Cancer Symposium
December 9th 2011, 3:50pm
San Antonio Breast Cancer Symposium
A collection of photos from the 34th annual SABCS at the Henry B. Gonzalez Convention Center in San Antonio, TX, from December 6-10, 2011.